Qiagen has joined the investors in diagnostic testing company Protagen, the month after the two signed a collaboration agreement.

Protagen, a Germany-based developer of diagnostic tests for autoimmune diseases, has reached the €10m ($12.3m) first close of a round backed by diagnostic technology provider Qiagen.

Qiagen, which participated in the round as a new investor, joined existing backers MIG Fonds, NRW.Bank, and members of Protagen’s management. Protgen has now raised €23.7m across its last three rounds, and its past investors include KfW and seed specialist S-Capital.

The round follows the singing of an agreement last month for Protagen and…